A CB2 receptor drug reduced cocaine-seeking behavior in rodents
The CB2 inverse agonist Xie2-64 reduced cocaine self-administration and reinstatement in rats without affecting food-seeking behavior.
Quick Facts
What This Study Found
Xie2-64, a CB2 receptor inverse agonist, dose-dependently reduced cocaine self-administration and blocked cocaine-primed reinstatement (relapse) in rats. Importantly, it did not reduce food-maintained responding, suggesting the effect was specific to drug reward rather than general motivation.
Key Numbers
Xie2-64 dose-dependently reduced cocaine self-administration; blocked cocaine-primed reinstatement at doses that did not affect food responding.
How They Did This
Animal study using rat models of cocaine self-administration, extinction, and reinstatement. Multiple dose levels of Xie2-64 were tested against vehicle controls.
Why This Research Matters
Current treatments for cocaine addiction are limited. This study suggests the CB2 receptor, part of the endocannabinoid system, could be a promising target for reducing cocaine abuse, opening a new therapeutic angle.
The Bigger Picture
The endocannabinoid system keeps revealing unexpected connections to addiction beyond cannabis. CB2 receptors, once thought to exist mainly in immune cells, are now recognized in the brain and appear to modulate reward circuits involved in multiple substances.
What This Study Doesn't Tell Us
Animal study; effects in rodents may not translate to humans. Only acute dosing was tested; long-term effects and safety are unknown. The specific compound (Xie2-64) has not been tested in humans.
Questions This Raises
- ?Would CB2-targeting drugs work for other stimulant addictions?
- ?Could Xie2-64 or similar compounds eventually reach human clinical trials?
Trust & Context
- Key Stat:
- Reduced cocaine self-administration without affecting food seeking
- Evidence Grade:
- Preliminary: animal study with a single compound; no human data available.
- Study Age:
- Published 2018.
- Original Title:
- Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents.
- Published In:
- Neuropharmacology, 176, 108241 (2020)
- Authors:
- Jordan, Chloe J(2), Feng, Zhi-Wei, Galaj, Ewa(6), Bi, Guo-Hua, Xue, Ying, Liang, Ying, McGuire, Terence, Xie, Xiang-Qun, Xi, Zheng-Xiong
- Database ID:
- RTHC-02638
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is a CB2 inverse agonist?
A drug that binds to CB2 cannabinoid receptors and produces the opposite effect of an agonist. Rather than activating the receptor, it reduces its baseline activity.
Could this lead to a cocaine addiction treatment?
Possibly. The results are promising but this is early-stage animal research. Human clinical trials would be needed to determine if CB2-targeting drugs are safe and effective for cocaine addiction.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-02638APA
Jordan, Chloe J; Feng, Zhi-Wei; Galaj, Ewa; Bi, Guo-Hua; Xue, Ying; Liang, Ying; McGuire, Terence; Xie, Xiang-Qun; Xi, Zheng-Xiong. (2020). Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents.. Neuropharmacology, 176, 108241. https://doi.org/10.1016/j.neuropharm.2020.108241
MLA
Jordan, Chloe J, et al. "Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents.." Neuropharmacology, 2020. https://doi.org/10.1016/j.neuropharm.2020.108241
RethinkTHC
RethinkTHC Research Database. "Xie2-64, a novel CB2 receptor inverse agonist, reduces cocai..." RTHC-02638. Retrieved from https://rethinkthc.com/research/jordan-2020-xie264-a-novel-cb2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.